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A B S T R A C T   
Organizing pneumonia (OP) is a sub-acute process of pulmonary tissue repair secondary to lung injury, defined 
histopathologically by intra-alveolar buds of granulation tissue within the lumen of distal pulmonary airspaces. It 
can be either cryptogenic or secondary (SOP) to different clinical conditions, namely infections. Despite being 
nonspecific, its diagnosis can be made by the association of clinical and imaging criteria. We report two cases of 
OP associated to SARS-CoV-2 pneumonia, admitted at a Portuguese tertiary hospital unit dedicated to COVID-19. 
Both patients presented with severe respiratory failure with need of invasive mechanical ventilation. After 
initial recovery, there was worsening of dyspnea and hypoxemic respiratory failure with increase in inflam-
matory markers. Chest CT revealed an OP pattern. Other conditions such as superinfection, auto-immune disease 
and iatrogenic etiology, were excluded and corticotherapy at a dose of 1 mg/kg/day was administered. Chest CT 
follow up of both our patients showed complete resolution of OP pattern, with mild to moderate residual pul-
monary fibrosis without honeycombing. 
There is no OP to SARS-CoV-2 case series yet published describing the progress of patients after cortico-
therapy, although the association between systemic corticosteroids and lower all-cause mortality in patients with 
COVID-19 has been recently established. It is possible that, as has been described with other viruses, OP sec-
ondary to SARS-CoV-2 represents an immunological process after initial infection, presenting with elevation of 
inflammatory markers and cytokines storm in the bloodstream and lung tissue, which may explain the favorable 
response to corticosteroids.   
1. Introduction 
Organizing pneumonia (OP) is a sub-acute process of pulmonary 
tissue repair secondary to lung injury. It is defined histopathologically 
by intra-alveolar buds of granulation tissue within the lumen of distal 
pulmonary airspaces. OP can be either cryptogenic or secondary to 
different clinical conditions, as infections, connective tissue diseases, 
malignancies, organ transplants, radiotherapy or certain drugs [1,2]. 
Despite being nonspecific, its diagnosis can be made by the association 
of imaging and clinical criteria [3], in particular evidence of multiple 
bilateral and peripheral alveolar opacities after initial improvement of 
fever and dyspnea [4]. The majority of patients respond to corticoste-
roids in addition to treatment for the underlying condition of secondary 
organizing pneumonia (SOP), often resulting in rapid clinical and 
radiological improvement. Relapses can nevertheless occur after treat-
ment suspension [1,2]. 
Several case series of chest computed tomography (CT) [5–8] and 
autopsy findings associating SARS-CoV-2 infection to OP have been 
published [9], one with histological confirmation with transbronchial 
biopsy [10]. However, unlike SOP associated to other coronavirus 
(CoV), as severe acute respiratory syndrome (SARS) and Middle East 
respiratory syndrome [4,11,12], and Influenza A and B [3], there is 
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sparse information regarding the clinical course of SOP to SARS-CoV-2. 
We report two cases of OP associated to SARS-CoV-2 pneumonia, 
admitted at a Portuguese tertiary hospital unit dedicated to COVID-19 
patients in March 2020, and successfully treated with corticotherapy. 
1.1. Case description 1 
A 71-year-old man, with past medical history of arterial hypertension 
and type 2 diabetes mellitus, presented to the emergency department 
with fever (40 ◦C) for seven days. He had been diagnosed with COVID- 
19 two days earlier by RT-PCR testing of nasopharyngeal swab. On 
physical examination, the patient was febrile (39,2 ◦C), hypertensive 
(186/94 mmHg), tachycardic (107 bpm), with 96% peripheral oxygen 
saturation on room air and had bilateral rhonchi on lung auscultation. 
Blood tests showed lymphopenia (970 lymphocytes/μL) and eleva-
tion of fibrinogen (6.78 g/L), CRP (124 mg/L), LDH (378 U/L) and AST 
(45 U/L); PCT and DD were at normal range. He also had respiratory and 
metabolic alkalemia on room air (pH 7.626, PaO2 146 mmHg, PaCO2 
28.1 mmHg, HCO3− 32.6 mmol/L), with serum lactate of 2.0 mg/dL. 
Chest CT scan revealed multiple bilateral ground-glass opacities in all 
pulmonary lobes, with predominant peripheral and lower lobe distri-
bution, with no pleural effusion or adenopathies, consistent with mod-
erate to severe COVID-19 pneumonia. Considering the clinical 
symptoms and extent of pulmonary involvement on chest CT scan, the 
patient was admitted to COVID-19 dedicated Unit. Lopinavir/ritonavir 
(LOP/r) 400 g/50 mg bid and hydroxychloroquine (HCQ) 200 mg bid 
were started, according to institutional directives at that time, as well as 
prophylactic Enoxaparin. 
In the first 48 hours after admission, the patient developed hypox-
emic respiratory failure, with PaO2 of 60 mmHg under FiO2 of 60%. He 
was admitted to an Intensive Care Unit (ICU) for 17 days, with invasive 
mechanical ventilation for 15 days and two sessions of prone-position 
ventilation. Treatment with LOP/r and HCQ was maintained for a 
total of 10 days and the patient was medicated with ceftriaxone and 
azithromycin, although there was no laboratory confirmation of bacte-
rial infection. 
ICU discharge occurred at 22nd day of disease diagnosis, and the 
patient was readmitted at the COVID-19 dedicated Unit. He was afebrile, 
had no signs of respiratory distress and his blood oxygen saturation was 
94% on room air. On the 30th day of disease, the patient developed 
dyspnea and hypoxemic respiratory failure with increase in inflamma-
tory markers (Table 1). Chest CT scan revealed patchy linear-band 
opacities with curvilinear morphology and perilobular distribution, 
consistent with radiological pattern of OP, with >75% extension of lung 
parenchymal involvement (Fig. 1). A presumptive diagnosis of OP was 
made based on clinical and chest CT findings and prednisolone was 
started at a dose of 1 mg/kg/day. After 36 hours of treatment, the pa-
tient experienced significant clinical improvement, with apyrexia, dys-
pnea relief and progressive decrease of supplementary oxygen. Bacterial 
infection, autoimmune diseases and HIV infection were excluded. 
Nasopharyngeal swab for SARS-CoV-2 was negative and serology for 
SARS-CoV-2 revealed antibody response (positive IgG: 22.03 UA/mL, 
positive IgM: 1.03 UA/mL). 
After 7 days of corticotherapy, the patient fully recovered from res-
piratory failure. He completed 16 days of full dose of corticosteroids that 
were tapered over 13 weeks. The patient initiated physical rehabilita-
tion and was discharged on the 52nd day of disease. Chest CT performed 
in the last week of corticotherapy showed complete resolution of OP 
pattern, with mild to moderate residual pulmonary fibrosis. 
1.2. Case description 2 
An 83-year-old man was admitted with progressive dyspnea with 1- 
week duration. The patient denied fever, cough, orthopnea, nocturnal 
paroxysmal dyspnea or gastrointestinal symptoms. He had a history of 
arterial hypertension, type 2 diabetes mellitus and rectal cancer treated 
with abdominoperineal resection with permanent colostomy in 2006. 
On admission at the emergency department, the patient was tachy-
cardic (120 bpm) and hypertensive (156/77 mmHg), with 72% pe-
ripheral oxygen saturation on room air and diminished breath sound at 
the base of the right lung. Laboratory tests showed leukocytosis (18200/ 
μL) with neutrophilia (16230/μL) and normal lymphocyte levels (1290/ 
μL), and elevated inflammatory markers (CRP 354 mg/L, PCT 0.46 ng/ 
mL, DD 3.5 mg/L, ferritin 1863 ng/mL, LDH 721 U/L, AST 67 U/L, ALT 
86 U/L). Arterial blood analysis demonstrated a respiratory and meta-
bolic alkalemia and a type I respiratory failure with 40% of FiO2 (pH 
7.51, PaO2 60.9 mmHg, PaCO2 31.4 mmHg, SatO2 92.6%, HCO3− 26.9 
mmol/L). Lactate was normal. Chest radiograph showed bilateral 
interstitial patchy airspace opacities with predominant lower lung zone 
distribution. The nasopharyngeal swab RT-PCR test was positive for 
SARS-CoV-2 infection and the patient was admitted to a COVID-19 
dedicated Unit. 
In the first 24 hours after admission, he developed severe acute 
respiratory distress syndrome (ARDS), with PaO2 of 50.4 mmHg under 
FiO2 of 60%, and was transferred to the ICU. He was medicated with 
LOP/r and HCQ (suspended 4 days later due to development of pro-
longed QT interval) and was discharged at the 20th day of disease, after 
12 days of invasive mechanical ventilation. The patient was readmitted 
at our Unit on 2L/min of supplemental oxygen, but on 30th day of 
COVID-19 symptoms, he presented with elevated inflammatory markers 
(Table 1) and worsening of hypoxemia, which were not resolved by that 
time. 
Chest CT scan revealed extensive areas of airspace disease with 
patchy ground-glass opacities and consolidations with peripheral and 
peribronchic distribution, predominantly in the mid and lower lung 
zones (Fig. 2). OP diagnosis was considered, and methylprednisolone 
was initiated at the dose of 1 mg/kg/day. Respiratory failure improved 
in the first 24 hours, but exacerbated again in the second day of corti-
cotherapy, leading to readmission in the ICU on the 32nd day of disease. 
High flow nasal cannula oxygen (maximum of 30L/60% FiO2) and 
negative fluid balance strategy was initiated, maintaining the same dose 
of methylprednisolone. RT-PCR assay for SARS-CoV-2 was negative and 
Table 1 
Comparison of clinical features and organizing pneumonia’s progress between 
patient 1 and patient 2.  
Organizing 
Pneumonia 
Patient 1 Patient 2 
Time of 
presentation 
30th day of disease (8 days 
after ICU discharge) 
30th day of disease (10 days 
after ICU discharge) 
Signs and 
symptoms 










CRP (mg/L) 217 287 
PCT (ng/mL) 0,5 0,36 
Ferritin (ng/mL) 1249 1574 
DD (mg/L) 1,5 3,62 
Fibrinogen (g/L) 6,3 6,76 
LDH (U/L) 454 451 
AST (U/L) 37 31 
ALT (U/L) 37 35 





7 days 6 days 
Duration of 
corticotherapy 
15 weeks 15 weeks 
CT scan after 
treatment 
resolution of OP pattern, 
mild to moderate residual 
pulmonary fibrosis 
resolution of OP pattern, mild 
residual pulmonary fibrosis  
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serology for SARS-CoV-2 revealed antibody response (positive IgG: 
20.45 UA/mL, negative IgM: 0.98 UA/mL). Blood, sputum and bronchial 
secretions’ cultures were negative for infectious agents and autoimmune 
diseases and HIV were excluded. 
The patient was discharged from ICU on the 36th day without sup-
plemental oxygen. On the 43rd day of disease, subacute pulmonary 
thromboembolism was diagnosed on CT pulmonary angiography and 
treated with anticoagulation. Full dose of methylprednisolone was 
maintained for 20 days and tapered for 13 weeks. Chest CT performed 1 
month after corticosteroid suspension showed resolution of pulmonary 
consolidations with mild residual patchy ground glass opacities, retic-
ulation and traction bronchiectasis consistent with resolution of OP 
radiological pattern and mild residual pulmonary fibrosis. 
2. Discussion 
We describe two cases with SARS-CoV-2 infection associated with OP 
diagnosis based on clinical and imaging findings. The majority of OP 
secondary to coronaviruses’ cases are not confirmed histologically with 
transbronchial, percutaneous or open lung biopsies [4,10,12], although 
some cases are confirmed post-mortem [13]. OP secondary to viral in-
fections are usually suspected when the patient is improving with spe-
cific treatment for pneumonia and clinical deterioration occurs, 
presenting with new fever, increasing inflammatory markers and 
worsening oxygen exchange and respiratory mechanics [14]. After 
excluding other conditions such as superinfection, auto-immune disease 
and iatrogenic etiology, the clinical hypothesis of OP can be supported 
with a characteristic chest CT radiological pattern that includes migra-
tory lung parenchymal opacities, patchy consolidations and ground 
glass opacities with peripheral or peribronchial distribution and air 
bronchograms and ectatic bronchi, linear opacities with perilobular 
distribution, reversed halo sign and crazy paving [1]. Clinical confir-
mation is often presumed with a successful clinical and imaging treat-
ment response to corticosteroids, as occurred with both our patients. 
In COVID-19 pandemic, patients presently with acute respiratory 
symptoms and a characteristic radiological CT pattern with organizing 
pneumonia features are associated with high probability of SARS-CoV-2 
infection. They may be used in association with RT-PCR tests to diagnose 
Fig. 1. Chest CT axial images of COVID-19 pneumonia of patient 1. Diffuse patchy consolidations and ground-glass opacities in the sub-acute phase with band 
opacities with perilobular distribution (panel A). Chest CT performed in the last week of corticotherapy demonstrating radiological resolution of airspace disease with 
mild residual reticular opacities and traction bronchiectasis representing pulmonary fibrosis without honeycombing (panel B). 
Fig. 2. Chest CT axial images of COVID-19 pneumonia of patient 2. Patchy consolidations and ground-glass opacities with signs of organizing pneumonia in the sub- 
acute phase (panel A). Chest CT performed 1 month after corticosteroid suspension, demonstrating radiological resolution of airspace disease with mild residual 
pulmonary fibrosis without honeycombing (panel B). 
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and triage patients for hospital admission and treatment [15]. 
There is no OP to SARS-CoV-2 case series published at current time, 
describing the progress of patients after corticotherapy, although the 
association between systemic corticosteroids and lower all-cause mor-
tality in patients with COVID-19 has been established in the previous 
months by the Who REACT Group [16], RECOVERY Collaborative 
Group [17] and Chopra et al. [18]. 
OP secondary to other coronaviruses improves clinically and on 
imaging, but there is uncertainty about the treatment duration, time 
course of response and the optimal timing for corticosteroid tapering. 
Dosage of methylprednisolone used for OP diverges between 0,5 and 1,5 
mg/kg/day and course of treatment varies from 2 months to one year, 
with no recurrence after corticoid suspension in most patients [1,12–14, 
19]. 
It has been suggested that OP secondary to viruses’ infection de-
velops after the replicative phase, since clinical presentation is subacute, 
occurring several weeks after the first symptoms [3] and often with 
undetectable viral particle in PCR assay. As with other viruses, SOP to 
SARS-CoV-2 may emerge as a result of an immunological process after 
initial infection, leading to elevation of inflammatory markers triggered 
by cytokines storm in the bloodstream and lung tissue, which may 
explain the favorable response to corticosteroids, in the absence of 
additional therapy such as antibiotics or therapeutic anticoagulation 
[13]. Different response timing may be attributable to pulmonary 
microthrombotic events or fluid overload [9]. In our two patients, IL-6 
was not measured in the bloodstream during symptomatic disease, so 
we could not confirm an association with the extent of inflammation 
using this marker. SARS-CoV-2-IgG and IgM although detectable, cannot 
be used to extrapolate the magnitude of disease or response to treatment 
[20]. 
3. Conclusion 
As noted previously, the use of immunomodulators in COVID-19 may 
be counterproductive as their use may delay eradication of the virus 
[21]. However, corticosteroids used during the inflammatory phase of 
COVID-19 improve prognosis and mortality [17]. 
It is not known if treatment of OP secondary to SARS-CoV-2 with 
corticosteroids, especially after ARDS and invasive mechanical ventila-
tion, can prevent or decrease the development of residual pulmonary 
fibrosis. Large scale studies are needed to determine optimal indication, 
dosage and duration of corticotherapy in acute symptomatic SARS-CoV- 
2 infection. Clinical follow-up of these patients is required to better 
understand the disease course and long-term sequela. 
We suspect that OP is much more common in SARS-CoV-2 despite the 
few reports until this day. Its timely diagnosis and treatment may lead to 
less ventilatory support, less redundant antibiotics and improving in 
overall survival. 
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